Company Description
Biodesix, Inc. operates as a data-driven diagnostic solutions company in the United States.
The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests, together marketed as part of Nodify Lung Nodule Risk Assessment testing strategy, to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules.
It also provides GeneStrat ddPCR and NGS, and VeriStrat tests, which are used in the diagnosis of lung cancer to measure the presence of mutations in the tumor and the state of the patient's immune system to establish the patient's prognosis and help guide treatment decisions.
In addition, the company, through its partnership with Bio-Rad Laboratories, Inc., provides Bio-Rad SARS-CoV-2 ddPCR, a COVID-19 Test under Biodesix WorkSafe testing program; and Platelia SARS-CoV-2 Total Ab test, an antibody test for detecting a B-cell immune response to SARS-CoV-2 that indicate recent or prior infection.
Further, it offers diagnostic and clinical research, as well as clinical trial testing services to biopharmaceutical companies; and discovers, develops, and commercializes companion diagnostics.
The company was formerly known as Elston Technologies, Inc. and as changed to Biodesix, Inc. in 2006.
Biodesix, Inc. was incorporated in 2005 and is headquartered in Louisville, Colorado.
| Country | United States |
| IPO Date | Oct 28, 2020 |
| Industry | Diagnostics & Research |
| Sector | Healthcare |
| Employees | 217 |
| CEO | Scott Hutton |
Contact Details
Address: 2970 Wilderness Place, Suite 100 Boulder, Colorado 80301 United States | |
| Phone | 303-417-0500 |
| Website | biodesix.com |
Stock Details
| Ticker Symbol | BDSX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $18.00 |
| CIK Code | 0001439725 |
| CUSIP Number | 09075X108 |
| ISIN Number | US09075X1081 |
| Employer ID | 20-3986492 |
| SIC Code | 8071 |
Key Executives
| Name | Position |
|---|---|
| Scott Hutton | President, Chief Executive Officer and Director |
| Robin Harper Cowie | Chief Financial Officer, Secretary and Treasurer |
| Dr. Heinrich Röder | Founder and Chief Technology Officer |
| Christopher Vazquez | Vice President, Controller and Chief Accounting Officer |
| Mark DeBlock | Vice President of Sales |
| Robbie Lunt | Senior Director of Marketing |
| Jessica Olbricht | Senior Director of Human Resources |
| Dr. Gary Anthony Pestano Ph.D. | Chief Development Officer |
| Bobbi Coffin | Chief Growth Officer |
| Dr. James R. Jett M.D. | Co-Chief Medical Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 23, 2024 | S-1 | General form for registration of securities under the Securities Act of 1933 |
| Apr 16, 2024 | PRE 14A | Other preliminary proxy statements |
| Apr 9, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| Apr 9, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| Apr 9, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| Apr 9, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| Apr 9, 2024 | 8-K | Current Report |
| Apr 5, 2024 | 424B5 | Filing |
| Apr 5, 2024 | 424B5 | Filing |
| Mar 1, 2024 | 10-K | Annual Report |